{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:02:41Z","timestamp":1790128961552,"version":"4.0.1"},"reference-count":35,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT 219417"],"award-info":[{"award-number":["WT 219417"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Rare Disease Translational Research Collaboration"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipodystrophy syndromes (LD) are a group of rare conditions characterized by the generalized or partial absence and\/or dysfunction of adipocytes. Due to the lack of fat storage capacity, excess lipid accumulates in other tissues, leading to severe insulin resistance. At present, effective therapeutic options remain limited, with metreleptin currently the only specific licensed treatment. To this end, we evaluated the therapeutic impact of tirzepatide in people with partial lipodystrophy (PLD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center, retrospective, observational study, including all patients with PLD treated with tirzepatide between January 2022 and September 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty patients with PLD were included FPLD1 like = 26 (65%), FPLD2 = 4 (10%), FPLD3 = 7 (17.5%), FPLD7 = 1 (2.5%), APLD = 1 (2.5%), unclassified = 1 (2.5%). 87.5% (n = 35) were female with a median age of 47 years (IQR 39\u201459) and a median BMI of 31.5 kg\/m2 (IQR 27.3 to 35.5). After a median 9.5 month follow-up (IQR 7 to 11), marked reductions were seen in body weight from 91.0 kg (IQR 75.0 to 106.0) to 82.8 kg (IQR 69.0 to 93.4; P &amp;lt; .0001), in HbA1c from 65 mmol\/mol (IQR 54.5 to 85) to 52 mmol\/mol (IQR 39 to 62; P &amp;lt; .0001) and in serum triglycerides from 2.80 mmol\/L (IQR 1.6 to 3.7) to 1.83 mmol\/L (IQR 1.0 to 2.9; P = .0005). Daily insulin requirements fell from 177.5 IU (IQR 101.3 to 213.8) to 58.0 IU (IQR 0 to 112.5; P = .0028).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with partial lipodystrophy, tirzepatide use resulted in substantial statistically significant reductions in weight, glycemic control, serum triglycerides, and daily insulin requirement. We recommend further prospective studies to support these findings and to evaluate its impact earlier in the course of the disorder.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag126","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:40:49Z","timestamp":1773924049000},"page":"e2146-e2153","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1234-4260","authenticated-orcid":false,"given":"Mandour O","family":"Mandour","sequence":"first","affiliation":[{"name":"University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science , Cambridge CB2 0QQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stears","sequence":"additional","affiliation":[{"name":"National Severe Insulin Resistance Service, Wolfson Diabetes and Endocrinology Clinic, Cambridge University Hospitals NHS Trust , Cambridge CB2 0QQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agatha","family":"Van Der Klaauw","sequence":"additional","affiliation":[{"name":"University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science , Cambridge CB2 0QQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Flanagan","sequence":"additional","affiliation":[{"name":"National Severe Insulin Resistance Service, Wolfson Diabetes and Endocrinology Clinic, Cambridge University Hospitals NHS Trust , Cambridge CB2 0QQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Gaff","sequence":"additional","affiliation":[{"name":"National Severe Insulin Resistance Service, Wolfson Diabetes and Endocrinology Clinic, Cambridge University Hospitals NHS Trust , Cambridge CB2 0QQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Jenkins","sequence":"additional","affiliation":[{"name":"National Severe Insulin Resistance Service, Wolfson Diabetes and Endocrinology Clinic, Cambridge University Hospitals NHS Trust , Cambridge CB2 0QQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Savage","sequence":"additional","affiliation":[{"name":"University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science , Cambridge CB2 0QQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"1","key":"2026081219572767500_dgag126-B1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.3714","article-title":"Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance","volume":"49","author":"Lotta","year":"2017","journal-title":"Nat Genet"},{"issue":"7","key":"2026081219572767500_dgag126-B2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2337\/db23-0575","article-title":"Relationship of fat mass ratio, a biomarker for lipodystrophy, with cardiometabolic traits","volume":"73","author":"Agrawal","year":"2024","journal-title":"Diabetes"},{"issue":"8","key":"2026081219572767500_dgag126-B3","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2337\/dc12-1529","article-title":"Type 2 diabetes with partial lipodystrophy of the limbs: a new lipodystrophy phenotype","volume":"36","author":"Strickland","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"2026081219572767500_dgag126-B4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ando.2024.05.022","article-title":"Leptin replacement therapy in the management of lipodystrophy syndromes","volume":"85","author":"Vigouroux","year":"2024","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"2026081219572767500_dgag126-B5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1172\/JCI77812","article-title":"The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux","volume":"126","author":"Samuel","year":"2016","journal-title":"J Clin Invest"},{"issue":"S1","key":"2026081219572767500_dgag126-B6","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH\u2014role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2026081219572767500_dgag126-B7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.arr.2006.03.004","article-title":"Lipotoxicity, overnutrition and energy metabolism in aging","volume":"5","author":"Slawik","year":"2006","journal-title":"Ageing Res Rev"},{"issue":"3","key":"2026081219572767500_dgag126-B8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"issue":"5","key":"2026081219572767500_dgag126-B9","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026081219572767500_dgag126-B10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"issue":"10","key":"2026081219572767500_dgag126-B11","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1210\/jc.2017-01235","article-title":"Roux-en-Y gastric bypass surgery in the management of familial partial lipodystrophy type 1","volume":"102","author":"Melvin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026081219572767500_dgag126-B12","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2337\/dc06-0130","article-title":"Effectiveness of gastric bypass surgery in a patient with familial partial lipodystrophy","volume":"29","author":"Utzschneider","year":"2006","journal-title":"Diabetes Care"},{"issue":"4","key":"2026081219572767500_dgag126-B13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11605-016-3300-2","article-title":"Successful treatment of an unusual case of FPLD2: the role of Roux-en-Y gastric bypass-case report and literature review","volume":"21","author":"Grundfest-Broniatowski","year":"2017","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"2026081219572767500_dgag126-B14","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2337\/dc23-1614","article-title":"Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy","volume":"47","author":"Foss-Freitas","year":"2024","journal-title":"Diabetes Care"},{"issue":"4","key":"2026081219572767500_dgag126-B15","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/dom.16175","article-title":"Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: real-life experience from a national reference network","volume":"27","author":"Lamothe","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2026081219572767500_dgag126-B16","doi-asserted-by":"crossref","first-page":"luad066","DOI":"10.1210\/jcemcr\/luad066","article-title":"A visual diagnosis: lipodystrophy","volume":"1","author":"Bhat","year":"2023","journal-title":"JCEM Case Rep"},{"key":"2026081219572767500_dgag126-B17","doi-asserted-by":"crossref","first-page":"1417613","DOI":"10.3389\/fgene.2024.1417613","article-title":"Case report: first Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Genet"},{"issue":"12","key":"2026081219572767500_dgag126-B18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/dme.13527","article-title":"Insulin secretory defect in familial partial lipodystrophy type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist","volume":"34","author":"Banning","year":"2017","journal-title":"Diabet Med"},{"issue":"1","key":"2026081219572767500_dgag126-B19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"2026081219572767500_dgag126-B20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"2026081219572767500_dgag126-B21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026081219572767500_dgag126-B22","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2337\/diacare.26.6.1819","article-title":"K\u00f6bberling type of familial partial lipodystrophy: an underrecognized syndrome","volume":"26","author":"Herbst","year":"2003","journal-title":"Diabetes Care"},{"key":"2026081219572767500_dgag126-B23"},{"issue":"10295","key":"2026081219572767500_dgag126-B24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"15","key":"2026081219572767500_dgag126-B25","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMc2211120","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Venniyoor","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2026081219572767500_dgag126-B26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabet.2017.10.014","article-title":"Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes","volume":"44","author":"Feldman-Billard","year":"2018","journal-title":"Diabetes Metab"},{"issue":"9","key":"2026081219572767500_dgag126-B27","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00125-025-06466-8","article-title":"Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study","volume":"68","author":"Buckley","year":"2025","journal-title":"Diabetologia"},{"issue":"7","key":"2026081219572767500_dgag126-B28","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","article-title":"Early worsening of diabetic retinopathy in the diabetes control and complications trial","volume":"116","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"2026081219572767500_dgag126-B29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"2026081219572767500_dgag126-B30","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/dom.14726","article-title":"Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: real-life experience from a national reference network","volume":"24","author":"Mosbah","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2026081219572767500_dgag126-B31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"key":"2026081219572767500_dgag126-B32","doi-asserted-by":"crossref","first-page":"154190","DOI":"10.1016\/j.metabol.2020.154190","article-title":"Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies","volume":"106","author":"Morieri","year":"2020","journal-title":"Metabolism"},{"issue":"5","key":"2026081219572767500_dgag126-B33","first-page":"756","article-title":"Metabolic improvements with tirzepatide in lipodystrophy: a novel option?","volume":"48","author":"Meral","year":"2025","journal-title":"Diabetes Care"},{"issue":"10313","key":"2026081219572767500_dgag126-B34","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2026081219572767500_dgag126-B35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag126\/67473102\/dgag126.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/9\/e2146\/67473102\/dgag126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/9\/e2146\/67473102\/dgag126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:57:37Z","timestamp":1786579057000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/9\/e2146\/8537219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag126","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,20]]}}}